miR-132及其抑制剂在心力衰竭中的研究进展  

Research progress of miR-132 and its inhibitors in heart failure

作　　者：王华 贾晓艳 刘永铭[2] WANG Hua;JIA Xiao-yan;LIU Yong-ming(The First Clinical Medical College of Lanzhou University,Lanzhou GANSU 730000,China;Department of Geriatric Cardiology,the First Hospital of Lanzhou University,Lanzhou GANSU 730000,China)

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730000 [2]兰州大学第一医院老年心血管科,甘肃兰州730000

出　　处：《中国新药与临床杂志》2024年第1期17-21,共5页Chinese Journal of New Drugs and Clinical Remedies

基　　金：甘肃省重点研发计划(20YF8FA079)。

摘　　要：miR-132是一种在心血管系统中普遍表达的调节RNA。当心脏组织中的miR-132高表达时,会影响与心肌细胞生长、自噬、钙处理和收缩等相关的信号通路,引起进行性不良心脏重构,从而导致心力衰竭事件。研究发现对miR-132的靶向抑制可减轻心脏肥大并改善心脏功能,给心衰患者带来一定的临床获益。一种优化的miR-132反义寡核苷酸抑制剂CDR132L的疗效及安全性首次在临床试验中得到证明。针对miR-132的反义寡核苷酸是未来缺血性或非缺血性心力衰竭的潜在治疗方法。miR-132 is a widely expressed regulatory RNA in the cardiovascular system.When miR-132 is highly expressed in cardiac tissues,it will affect the signaling pathways related to cardiomyocyte growth,autophagy,calcium processing and contraction,and cause progressive adverse cardiac remodeling,thus leading to heart failure events.Studies had found that targeted inhibition of miR-132 could reduce cardiac hypertrophy and improve cardiac function,bringing certain clinical benefits to patients with heart failure.CDR132L is a synthetic lead-optimized oligonucleotide inhibitor of miR-132.The efficacy and safety of CDR132L had been demonstrated for the first time in clinical trials.Antisense oligonucleotides targeting miR-132 are potential future therapies for ischemic or non-ischemic heart failure.

关 键 词：微RNAS miR-132 心力衰竭 心脏扩大 CDR132L 

分 类 号：R972.9[医药卫生—药品]